Family · Pharmaceutical analytical standards
Landiolol
An ultra-short-acting beta blocker, highly selective for the heart's beta-1 receptors, approved in Japan in 2002 for intravenous use: it quickly slows the heart rate in tachyarrhythmias, for example during or after surgery. This family brings together the active ingredient, nitrosamines and other impurities.
Did you know?Its half-life is about 4 minutes: once the infusion stops, the effect fades quickly. After Japan it reached Europe in 2016 and the United States only in 2024.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
